Development Pipeline & Plan

The company’s lead antibiotic programs SLP0904 and SLP0905 derived from chemical scaffolds of marine origin and have been developed to successfully treat infections caused by multi-drug resistant Gram positive pathogens e.g. VRE, MRSA, strains resistant to Mupirocin (antibiotic) and other broad spectrum antibiotics.

• SLP0905
  Systemic new class anti-Gram positive small molecule (iv and/or oral) at pre-clinical development stage.

• SLP0904
  Topical new class small molecule anti-Gram positive; ready for Phase I.

Pipeline activities in Gram-negative infections have led to:

• SLP0901
  Antimicrobial polymeric compound in pre-clinical stage against Gram-positive/Gram-negative bacteria,
  fungi and virus which has its origin in copying coral defense strategies.


Please find the current Sealife development programm on the right and click on it for a bigger view!